Enhanced sympathetic activity as a mechanism of Atrial Fibrillation

Amsterdam UMC0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Elective cardioversion is planned
•-Adequate anticoagulation with vitamin K antagonists or NOACs for at least 3 weeks prior to the procedure
•-Beta-blocker use at baseline, at least continued up to the second 123I-mIBG scintigraphy
•-Age between 18 and 80 years
•-Legally competent and willing and able to sign informed consent
•-Willing and able to conform to the study protocol

•-Unable or unwilling to comply with study procedures
•-Discontinuing of beta-blockers during follow-up period up to the second 123I-mIBG scintigraphy
•-Discontinuing or switch of antiarrhythmic drugs during follow-up period up to the second 123I-mIBG scintigraphyArrhythmia other than AF as the indication for cardioversion
•-Emergency electrical cardioversion
•-Overt heart failure symptoms (i.e. oedema, pulmonary rales, orthopnoea), NYHA class=2 and/or left ventricular ejection fraction < 35%
•-Known significant coronary artery disease (>50% stenosis)
•-Myocardial infarction or acute coronary syndrome within 3 months prior to the cardioversion
•-History of catheter or surgical ablation for any arrhythmia
•-A history of a thoracotomy
•-CVA within 6 months prior to the cardioversion
•-Active malignant disease
•-History of neurosecretory tumours
•-Pregnancy or of childbearing potential without adequate contraception
•-History of previous radiation therapy of the thorax
•-Circumstances that prevent follow-up (no permanent home or address, transient, etc.)
•-Life expectancy <2 years.

发起方

Amsterdam UMC